Enke_2025_J.Nucl.Med_66_1284

The objective of this study is to evaluate the PET biodistribution and radiation dosimetry of the fibroblast activation protein (FAP)-targeted tracer [(68)Ga]Ga-LNTH-1363S in cancer patients. Methods: Five patients with oncologic diseases (breast cancer, papillary thyroid carcinoma) were injected intravenously with 153-184 MBq of [(68)Ga]Ga-LNTH-1363S. PET/CT imaging was performed at 10, 60, and 180 min after administration of [(68)Ga]Ga-LNTH-1363S. Normal tissue dosimetry was performed following the MIRD dosimetry formalism. SUV analysis of normal tissues and tumors was performed. Results: The biodistribution of [(68)Ga]Ga-LNTH-1363S demonstrated rapid tumor uptake and efficient clearance from nontarget tissues, resulting in high tumor-to-background ratios at all imaging time points. The kidneys received the highest absorbed dose among normal tissues (0.038 +/- 0.01 mGy/MBq), followed by the pancreas and salivary glands. The tumor SUV(max) peaked at 10 min after injection (18.6 +/- 7.2) and remained high at later time points. No adverse events were observed during follow-up, and the effective dose (0.013 +/- 0.002 mSv/MBq) was consistent with other FAP tracers. Conclusion: [(68)Ga]Ga-LNTH-1363S offers favorable dosimetry and biodistribution profiles, comparable with other FAP-targeted tracers.